Orexigen Therapeutics (OREX) Misses Q2 EPS by 1c

Orexigen Therapeutics (NASDAQ: OREX) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $4.92 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c